Miconazole nitrate, zinc oxide and white petrolatum ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albica...
Miconazole nitrate, zinc oxide and white petrolatum ointment is not for oral, ophthalmic, or intravaginal use. Before applying miconazole nitrate, zinc oxide and white petrolatum ointment, gently cleanse the skin with lukewarm water and pat dry with a soft towel. Avoid using any scented soaps, shampoos, or lotions on the diaper area. Gently apply a thin layer of miconazole nitrate, zinc oxide and white petrolatum ...
Miconazole Nitrate, 0.25%, Zinc Oxide, 15% and White Petrolatum, 81.35% Ointment contains 2.5 mg of miconazole nitrate, USP, 150 mg of zinc oxide, USP and 813.5 mg of white petrolatum, USP per gram. The smooth, uniform, white ointment supplied in an aluminum tube is available as follows: NDC 0378-8222-50 carton containing one 50 gram tube Store at 20 ° to 25 ° C (68 ° to 77 ° F). [See USP Controlled Room Temperatu...
www.fda.gov/medwatchMiconazole nitrate, zinc oxide and white petrolatum ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment.
Miconazole nitrate, zinc oxide and white petrolatum ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes. Miconazole nitrate, zinc oxide and white petrolatum ointment should not be used as a substitute for frequent diaper changes.
The safety and efficacy of miconazole nitrate, zinc oxide and white petrolatum ointment have not been demonstrated in immunocompromised patients, or in infants less than 4 weeks of age (premature or term).
The safety and efficacy of miconazole nitrate, zinc oxide and white petrolatum ointment have not been evaluated in incontinent adult patients. Miconazole nitrate, zinc oxide and white petrolatum ointment should not be used to prevent the occurrence of diaper dermatitis, such as in an adult institutional setting, since preventative use may result in the development of drug resistance.
Miconazole nitrate, zinc oxide and white petrolatum ointment is not for oral, ophthalmic, or intravaginal use.
Before applying miconazole nitrate, zinc oxide and white petrolatum ointment, gently cleanse the skin with lukewarm water and pat dry with a soft towel. Avoid using any scented soaps, shampoos, or lotions on the diaper area.
Gently apply a thin layer of miconazole nitrate, zinc oxide and white petrolatum ointment to the diaper area with each diaper change for 7 days. Do not rub miconazole nitrate, zinc oxide and white petrolatum ointment into the skin as this may cause additional irritation. Thoroughly wash hands after applying miconazole nitrate, zinc oxide and white petrolatum ointment. Continue treatment for the full 7 days, even if there is improvement.
Do not use miconazole nitrate, zinc oxide and white petrolatum ointment for longer than 7 days. The safety of miconazole nitrate, zinc oxide and white petrolatum ointment when used for longer than 7 days is not known. If symptoms have not improved by day 7, see your health care provider.
Miconazole Nitrate, 0.25%, Zinc Oxide, 15% and White Petrolatum, 81.35% Ointment contains 2.5 mg of miconazole nitrate, USP, 150 mg of zinc oxide, USP and 813.5 mg of white petrolatum, USP per gram.
None
If irritation occurs or if the disease worsens, discontinue use of the medication, and contact the health care provider.
Because clinical trials are conducted under widely varying conditions, adverse reaction rate observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
A total of 835 infants and young children were evaluated in the clinical development program. Of 418 subjects in the miconazole nitrate, zinc oxide and white petrolatum ointment group, 58 (14%) reported one or more adverse events. Of 417 subjects in the zinc oxide/white petrolatum control group, 85 (20%) reported one or more adverse events. Adverse events that occurred at a rate of ≥ 1% for subjects who were treated with miconazole nitrate, zinc oxide and white petrolatum ointment were approximately the same in type and frequency as for subjects who were treated with zinc oxide/white petrolatum ointment.
The following adverse reactions have been identified during post approval use of miconazole nitrate, zinc oxide and white petrolatum ointment. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Gastrointestinal Disorders: vomiting
General Disorders and Administration Site Conditions: burning sensation, condition aggravated, inflammation, pain
Injury, Poisoning and Procedural Complications: accidental exposure
Skin and Subcutaneous Tissue Disorders: blister, dermatitis contact, diaper dermatitis, dry skin, erythema, pruritus, rash, skin exfoliation
Drug-drug interaction studies were not conducted. Women who take a warfarin anticoagulant and use a miconazole intravaginal cream or suppository may be at risk for developing an increased prothrombin time, international normalized ratio (INR), and bleeding. The potential for this interaction between warfarin and miconazole nitrate, zinc oxide and white petrolatum ointment is unknown.
There are no available data on miconazole nitrate, zinc oxide and white petrolatum ointment use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. In animal reproduction studies, prolonged gestation, increased number of resorptions, and decreased numbers of live young were observed after oral administration of miconazole nitrate during organogenesis to pregnant rats and rabbits. No comparisons of animal exposure with human exposure may be calculated due to minimal systemic exposure in humans after topical administration of miconazole nitrate, zinc oxide and white petrolatum ointment [see Clinical Pharmacology (12.3)].
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Miconazole nitrate administration has been shown to result in prolonged gestation and decreased numbers of live young in rats and in increased number of resorptions and decreased number of live young in rabbits at oral doses of 100 mg/kg/day and 80 mg/kg/day.
There is no available information on the presence of miconazole in human milk, or the effects on the breastfed child, or the effects on milk production following use of miconazole nitrate, zinc oxide and white petrolatum ointment.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for miconazole nitrate, zinc oxide and white petrolatum ointment and any potential adverse effects on the breastfed infant from miconazole nitrate, zinc oxide and white petrolatum ointment or from the underlying maternal condition.
Efficacy was not demonstrated in infants less than 4 weeks of age. Safety and efficacy have not been established in very-low-birth-weight infants (less than 1500 g).
Miconazole nitrate, zinc oxide and white petrolatum ointment should not be used to prevent diaper dermatitis.
The safety of miconazole nitrate, zinc oxide and white petrolatum ointment when used for longer than 7 days is not known. Do not use more than 7 days.
Safety and efficacy in a geriatric population have not been evaluated.
Miconazole nitrate, zinc oxide and white petrolatum ointment contains the synthetic antifungal agent, miconazole nitrate (0.25%) USP, zinc oxide (15%) USP, and white petrolatum (81.35%) USP.
The chemical name of miconazole nitrate is 1-[2, 4-dichloro-ß-{(2,4-dichlorobenzyl)oxy} phenethyl] imidazole mononitrate with empirical formula C18H14Cl4N2O•HNO3 and molecular weight of 479.15. The structural formula of miconazole nitrate is as follows:
The zinc oxide has an empirical formula of ZnO and a molecular weight of 81.39.
The white petrolatum, which is obtained from petroleum and is wholly or nearly decolorized, is a purified mixture of semisolid saturated hydrocarbons having the general chemical formula CnH2n+2. The hydrocarbons consist mainly of branched and unbranched chains. White petrolatum contains butylated hydroxytoluene (BHT) as stabilizer.
Each gram of miconazole nitrate, zinc oxide and white petrolatum ointment contains 2.5 mg of miconazole nitrate, USP, 150 mg of zinc oxide, USP and 813.5 mg of white petrolatum, USP containing butylated hydroxytoluene, trihydroxystearin, and Chemoderm 1001/B fragrance.
Miconazole nitrate, zinc oxide and white petrolatum ointment is a smooth, uniform, white ointment.
The miconazole component of miconazole nitrate, zinc oxide and white petrolatum ointment is an antifungal agent [see Clinical Pharmacology (12.4)]. The mechanism of action of white petrolatum and zinc oxide for the adjunctive treatment of diaper dermatitis is unknown.
The human pharmacodynamics of miconazole nitrate, zinc oxide and white petrolatum ointment is unknown [see Clinical Pharmacology (12.4) for fungal pharmacodynamics].
The topical absorption of miconazole from miconazole nitrate, zinc oxide and white petrolatum ointment was studied in immunocompetent male and female infants and children (n = 17) with diaper dermatitis complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast) ranging in age from 1 month to 21 months. After multiple daily applications to the affected area at every diaper change (approximately 5-12 times per day) for 7 days, the plasma concentrations of miconazole were below the lower limit of quantitation (LOQ) of 0.5 ng/mL in 15 out of 17 (88%) subjects. In the other 2 remaining subjects, the plasma concentrations of miconazole were 0.57 and 0.58 ng/mL, respectively at a single timepoint (4 hours after the last application) on Day 7.
The miconazole nitrate component in this product has been shown to have in vitro activity against Candida albicans, an organism that is associated with diaper dermatitis. The activity of miconazole nitrate against C. albicans is based on the inhibition of the ergosterol biosynthesis in the cell membrane. The accumulation of ergosterol precursors and toxic peroxides results in cytolysis of the cell. In vitro minimal inhibitory concentration (MIC) test results for C. albicans isolates obtained from treatment failures in Clinical Study 1 [see Clinical Studies (14)] does not appear to indicate that resistance to miconazole nitrate was the reason for treatment failure. The clinical significance of the in vitro activity of miconazole nitrate against C. albicans in the setting of diaper dermatitis is unclear.
The carcinogenic potential of miconazole nitrate, zinc oxide and white petrolatum ointment in animals has not been evaluated.
Miconazole nitrate was negative in a bacterial reverse mutation test, a chromosome aberration test in mice, and micronucleus assays in mice and rats.
Miconazole nitrate had no adverse effect on fertility in a study in rats at oral doses of up to 320 mg/kg/day.
Study 1 was a double-blind, multicenter study in which miconazole nitrate, zinc oxide and white petrolatum ointment was compared to the zinc oxide and white petrolatum combination treatment and included 236 infants and toddlers with diaper dermatitis, complicated by candidiasis as documented by KOH tests that demonstrated pseudohyphae and/or budding yeasts. Study medication was applied at every diaper change for 7 days.
The primary endpoint was “Overall Cure” and required that subjects be both clinically cured (total resolution of all signs and symptoms of infection) and microbiologically cured (eradication of candidiasis). Primary efficacy was assessed 1 week following the end of treatment, at Day 14.
Study results are shown in the following table.
Overall Cure at Day 14 | ||
| Miconazole Nitrate, Zinc Oxide and White Petrolatum Ointment | Zinc Oxide/White Petrolatum |
| 26 (23%) | 12 (10%) |
Two additional studies provided supportive evidence of the clinical efficacy of miconazole nitrate, zinc oxide and white petrolatum ointment in infants and toddlers with diaper dermatitis, some of whom cultured positive for C. albicans. However, candidal infection was not documented in the culture-positive subjects, as microscopic testing (e.g. KOH) was not done. Therefore, the positive culture results may have reflected colonization rather than infection.
Miconazole Nitrate, 0.25%, Zinc Oxide, 15% and White Petrolatum, 81.35% Ointment contains 2.5 mg of miconazole nitrate, USP, 150 mg of zinc oxide, USP and 813.5 mg of white petrolatum, USP per gram. The smooth, uniform, white ointment supplied in an aluminum tube is available as follows:
NDC 0378-8222-50
carton containing one 50 gram tube
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Keep out of reach of children.
See FDA-Approved Patient Labeling
Patients using miconazole nitrate, zinc oxide and white petrolatum ointment should be informed about the following information:
Miconazole Nitrate, Zinc Oxide and White Petrolatum Ointment |
Important Information:Miconazole nitrate, zinc oxide and white petrolatum ointment is for use on the skin only. Do not use miconazole nitrate, zinc oxide and white petrolatum ointment in the eyes, mouth, or vagina. |
What is miconazole nitrate, zinc oxide and white petrolatum ointment?
It is not known if miconazole nitrate, zinc oxide and white petrolatum ointment is safe and effective for use in incontinent adults. It is not known if miconazole nitrate, zinc oxide and white petrolatum ointment is safe and effective for use in children less than 4 weeks of age or very low birth weight (less than 1500 grams). |
Before using miconazole nitrate, zinc oxide and white petrolatum ointment, tell your child’s healthcare provider about all their medical conditions. |
How should I use miconazole nitrate, zinc oxide and white petrolatum ointment?
|
What should I avoid while using miconazole nitrate, zinc oxide and white petrolatum ointment?
|
What are the possible side effects of miconazole nitrate, zinc oxide and white petrolatum ointment? Miconazole nitrate, zinc oxide and white petrolatum ointment may cause serious side effects, including:
These are not all the possible side effects of miconazole nitrate, zinc oxide and white petrolatum ointment. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store miconazole nitrate, zinc oxide and white petrolatum ointment?
|
General information about the safe and effective use of miconazole nitrate, zinc oxide and white petrolatum ointment. |
What are the ingredients in miconazole nitrate, zinc oxide and white petrolatum ointment? Manufactured for: Mylan Pharmaceuticals Inc.,Morgantown, WV 26505 U.S.A. |
This Patient Information leaflet has been approved by the U.S. Food and Drug Administration.
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Manufactured by:
Confab Laboratories, Inc.
Saint-Hubert (QC) Canada J3Y 3X3
Revised: 8/2018
301923-02
CON:MZPOING:R2
NDC 0378-8222-50
Miconazole
Nitrate,
0.25%
Zinc Oxide,
15%
and White
Petrolatum,
81.35% Ointment
For Topical Use Only
Usual Dosage: See package insert.
Caution: Not for oral, ophthalmic, or
intravaginal use. Keep out of reach of
children. If seal is damaged or
punctured, do not use, and return
product to place of purchase.
Description: Each gram contains 2.5 mg
miconazole nitrate USP, 150 mg zinc
oxide USP, and 813.5 mg white
petrolatum USP containing butylated
hydroxytoluene, trihyforxystearin, and
Chemoderm 1001/B fragrance.
Store at 20º to 25ºC (68º to 77ºF).
[See USP Controlled Room
Temperature.]
See flap for lot number and expiration date.
For additional information, call Mylan at
1-877-446-3679 (1-877-4-INFO-RX).
Serious side effects associated with the
use of this product may be reported to
this number.
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Made in Canada
CON:8222:50:1C:R1 301922-01
Mylan.com
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 831391 | miconazole nitrate 0.25 % / zinc oxide 15 % / petrolatum 81.4 % Topical Ointment | PSN | 3 |
| 831393 | Vusion 0.25 % / 15 % / 81.35 % Topical Ointment | PSN | 3 |
| 831393 | miconazole nitrate 0.0025 MG/MG / petrolatum 0.814 MG/MG / zinc oxide 0.15 MG/MG Topical Ointment [Vusion] | SBD | 3 |
| 831391 | miconazole nitrate 0.0025 MG/MG / petrolatum 0.814 MG/MG / zinc oxide 0.15 MG/MG Topical Ointment | SCD | 3 |
| 831391 | Miconazole Nitrate 0.0025 MG/MG / Petrolatum 0.814 MG/MG / ZNO 0.15 MG/MG Topical Ointment | SY | 3 |
| 831393 | Miconazole Nitrate 0.0025 MG/MG / Petrolatum 0.814 MG/MG / ZNO 0.15 MG/MG Topical Ointment [Vusion] | SY | 3 |
| 831391 | miconazole nitrate 0.25 % / petrolatum, white 81.35 % / zinc oxide 15 % Topical Ointment | SY | 3 |
| 831393 | Vusion (miconazole nitrate 0.25 % / petrolatum, white 81.35 % / zinc oxide 15 % ) Topical Ointment | SY | 3 |
| Class | Version | Type | Effective |
|---|---|---|---|
| MICONAZOLE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 3a55f4fb-5aec-4c88-0ff7-4d608ad4866a | Product name | 1 | 20140508 |
| 5b9a7965-36d2-8412-dcaf-f76a65411611 | Product name | 1 | 20140508 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0378-8222-50 | VUSION | 50 g in 1 TUBE | OINTMENT | 50 | 3 | |
| 0378-8222-50 | VUSION | 1 in 1 CARTON | OINTMENT | 1 | 3 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0378-8222-50 | GM - Gram | 0378-8222 | 52903dae-91dc-45d2-91cf-b54cecc3f837 | 1 | 2018-12-13 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0378-8222 | 0378-8222-50 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| MICONAZOLE NITRATE | VW4H1CYW1K | ACTIB |
| ZINC OXIDE | SOI2LOH54Z | ACTIB |
| PETROLATUM | 4T6H12BN9U | ACTIB |
| BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | IACT |
| TRIHYDROXYSTEARIN | 06YD7896S3 | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021026-001 | VUSION | MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N021026-001 | VUSION | 0.25%;81.35%;15% | OINTMENT / TOPICAL | RLD, RS | 2006-02-16 | f41ea6bd6efb… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N021026-001 | 8147852 | 2028-03-30 | U-1426 | 2013-09-11 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| VUSION | MICONAZOLE NITRATE, ZINC OXIDE, WHITE PETROLATUM | Mylan Pharmaceuticals Inc. | b026bc7d-3a18-41e8-88c4-1e063cd2f42c | 2018-08-14 | Warnings, Adverse reactions | 0378-8222-50 0378-8222 00378822250 1b5de1cf-d19f-424b-86c0-e2ebcb0b3cf0 b026bc7d-3a18-41e8-88c4-1e063cd2f42c |
Adverse event summaries are temporarily unavailable. Other product information remains available.